WntResearch AB (publ) and EMD Millipore have entered into a non-exclusive license agreement that allows EMD Millipore to produce and sell the Box-5 drug candidate for research applications.
The Box-5 drug candidate is an inhibitor of Wnt-5a signaling with the same amino acid backbone as WntResearch's lead drug candidate Foxy-5. The Box-5 drug candidate for research use is expected to be a niche product from which WntResearch will receive a double digit royalty on net sales and drug product for quality monitoring purposes.
CEO Bert Junno comments:
"There is an increasing and high demand, from researchers, for an inhibitor (Box-5) acting on the Wnt-5a signalling pathway and we have received many requests for material. I am pleased to enter into this agreement together with a well established producer that can deliver a high quality product to interested scientists. There are, in addition to cancer research, several other large areas such as lung, heart and bone growth related diseases that could potentially be of interest to scientists/researchers.
EMD Millipore, a division of Merck KGaA, Darmstadt, Germany, offers solutions that enable scientists to conduct life science research easily, efficiently and economically. With a range of more than 40,000 products, EMD Millipore is one of the top three suppliers of tools to the life science industry. For more information:www.emdmillipore.com
WntResearch (WNT.ST) is listed on the Aktietorget stock exchange and the business is based on research from Lund University. The focus and purpose of WntResearch is to develop new drugs against metastatic cancers. The company has two major development projects, Foxy-5 and Box-5. The main project is the Foxy-5, which is currently being tested in in vivo models and is planned to start and complete the Phase 1 clinical trials of metastatic cancer in 2012.
For more information contact:
Bert Junno, CEO
WntResearch AB (publ)